New radioactive drug targets Hard-to-Treat melanoma

NCT ID NCT07076550

First seen Jan 04, 2026 · Last updated May 03, 2026 · Updated 18 times

Summary

This early-stage trial tests an investigational drug for adults with melanoma that has spread or cannot be removed by surgery. The main goals are to find the safest dose and see what side effects occur. Participants receive the drug once every 6 weeks for up to 6 doses, along with regular checkups. The study also looks at whether the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alfred Health

    RECRUITING

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Austin Health

    RECRUITING

    Melbourne, Victoria, 3084, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fiona Stanley Hospital

    NOT_YET_RECRUITING

    Murdoch, Western Australia, 6150, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • GenesisCare Murdoch

    NOT_YET_RECRUITING

    Murdoch, Western Australia, 6150, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.